Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease

被引:30
作者
Zhang, Xinrong [1 ,2 ,3 ]
Wong, Grace Lai-Hung [1 ,2 ,3 ]
Yip, Terry Cheuk-Fung [1 ,2 ,3 ]
Cheung, Johnny T. K. [1 ]
Tse, Yee-Kit [1 ,2 ,3 ]
Hui, Vicki Wing-Ki [1 ,2 ,3 ]
Lin, Huapeng [1 ,2 ,3 ]
Lai, Jimmy Che-To [1 ,2 ,3 ]
Chan, Henry Lik-Yuen [2 ,4 ]
Kong, Alice Pik-Shan [1 ]
Wong, Vincent Wai-Sun [1 ,2 ,3 ]
机构
[1] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong Sar, Peoples R China
[2] Chinese Univ Hong Kong, Med Data Analyt Centre, Hong Kong, Hong Kong Sar, Peoples R China
[3] Chinese Univ Hong Kong, Inst Digest Dis, Fac Med, Hong Kong, Hong Kong Sar, Peoples R China
[4] Union Hosp, Hong Kong, Hong Kong Sar, Peoples R China
关键词
cirrhosis; fibrosis scores; liver cancer; nonalcoholic steatohepatitis; type 2 diabetes mellitus; HEPATOCELLULAR-CARCINOMA; ASSOCIATION; POPULATION; PREVALENCE; FIBROSIS; THIAZOLIDINEDIONES; INDIVIDUALS; MODEL;
D O I
10.1002/hep.32476
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims Several guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of age and duration of T2D for liver-related event development to guide screening strategies. Approach and Results We conducted a territory-wide retrospective cohort study of adult patients with NAFLD and T2D diagnosed between 2000 and 2014 in Hong Kong to allow for at least 5 years of follow-up. The primary endpoint was liver-related events, defined as a composite of HCC and cirrhotic complications. This study included 7028 patients with NAFLD with T2D (mean age, 56.1 +/- 13.3 years; 3363 male [47.9%]). During a follow-up of 77,308 person-years, there was a threshold effect with 1.1%, 4.9%, and 94.0% of patients developing liver-related events at the age of <40, 40-50, and >= 50 years, respectively. Similarly, 3.1%, 5.1%, and 91.8% of patients developed cirrhosis at the age of <40, 40-50, and >= 50 years, respectively. In contrast, liver-related events increased linearly with diabetes duration, with no difference in the annual incidence rate between the first 10 years of T2D diagnosis and subsequent years (0.06% vs. 0.10%; p = 0.136). On multivariable analysis, baseline age >= 50 years (adjusted HR [aHR] 2.01) and cirrhosis (aHR 3.12) were the strongest risk factors associated with liver-related events. Substitution of cirrhosis with the aspartate aminotransferase-to-platelet ratio index or the Fibrosis-4 index yielded similar results. Conclusions Age rather than duration of T2D predicts liver-related events in patients with NAFLD and T2D. It is reasonable to screen patients with NAFLD and T2D for advanced liver disease starting at 50 years of age.
引用
收藏
页码:1409 / 1422
页数:14
相关论文
共 50 条
  • [21] ACE inhibitors/angiotensin receptor blockers prevent liver-related events in nonalcoholic fatty liver disease
    Zhang, Xinrong
    Wong, Grace Lai-Hung
    Yip, Terry Cheuk-Fung
    Tse, Yee-Kit
    Liang, Lilian Yan
    Hui, Vicki Wing-Ki
    Lin, Huapeng
    Li, Guan-Lin
    Lai, Jimmy Che-To
    Chan, Henry Lik-Yuen
    Wong, Vincent Wai-Sun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 51 - 52
  • [22] Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective
    Rhee, Eun-Jung
    ENDOCRINOLOGY AND METABOLISM, 2019, 34 (03) : 226 - 233
  • [23] Identifying patients at risk from nonalcoholic fatty liver-related hepatocellular carcinomas
    Sayiner, Mehmet
    Younossi, Zobair M.
    HEPATIC ONCOLOGY, 2016, 3 (02) : 101 - 103
  • [24] Mortality and Liver-Related Events in Lean Versus Non-Lean Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
    Ha, Jane
    Yim, Sun Young
    Karagozian, Raffi
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (10) : 2496 - +
  • [25] Association of statins with nonalcoholic fatty liver disease in patients with diabetes
    Shah, Raj
    Kong, Alexander
    De Melo, Silvio
    Boktor, Moheb
    Henriquez, Richard
    Mandalia, Amar
    Samant, Hrishikesh
    Alvarez, Carlos A.
    Mansi, Ishak A.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2024, 72 (06) : 497 - 510
  • [26] Factors related to the presence of nonalcoholic fatty liver disease in patients with type 2 diabetes: a single center study
    Akin, Seydahmet
    Gungor, Oguzhan
    Boyuk, Banu
    Erman, Hande
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 272 - 278
  • [27] Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis
    Pennisi, Grazia
    Enea, Marco
    Romero-Gomez, Manuel
    Vigano, Mauro
    Bugianesi, Elisabetta
    Wong, Vincent W. -s
    Fracanzani, Anna Ludovica
    Sebastiani, Giada
    Boursier, Jerome
    Berzigotti, Annalisa
    Eslam, Mohammed
    Ampuero, Javier
    Benmassaoud, Amine
    La Mantia, Claudia
    Mendoza, Yuly P.
    George, Jacob
    Craxi, Antonio
    Camma', Calogero
    de Ledinghen, Victor
    Petta, Salvatore
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (05) : 604 - 615
  • [28] NONALCOHOLIC FATTY LIVER DISEASE AND RISK OF DIABETES: A PROSPECTIVE STUDY IN CHINA
    Shen, Xiuhua
    Cai, Fianfang
    Gao, Fingsheng
    Vaidya, Anand
    Liu, Xuemei
    Li, Wen
    Chen, Shuohua
    Zhou, Yong
    Li, Yinge
    Zhang, Yanmin
    Zhao, Jianqiu
    Hu, Frank B.
    Wu, Shouling
    Gao, Xiang
    ENDOCRINE PRACTICE, 2018, 24 (09) : 823 - 832
  • [29] Update on cardiovascular risk in nonalcoholic fatty liver disease
    Johnston, Michael P.
    Patel, Janisha
    Byrne, Christopher D.
    CURRENT OPINION IN CARDIOLOGY, 2021, 36 (04) : 478 - 486
  • [30] Nonalcoholic fatty liver disease
    Erickson, Sandra K.
    JOURNAL OF LIPID RESEARCH, 2009, 50 : S412 - S416